These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 32565912)

  • 1. Orodispersible budesonide tablets for the treatment of eosinophilic esophagitis: a review of the latest evidence.
    Miehlke S; Lucendo AJ; Straumann A; Jan Bredenoord A; Attwood S
    Therap Adv Gastroenterol; 2020; 13():1756284820927282. PubMed ID: 32565912
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evidence-based treatments for eosinophilic esophagitis: insights for the clinician.
    Feo-Ortega S; Lucendo AJ
    Therap Adv Gastroenterol; 2022; 15():17562848211068665. PubMed ID: 35069803
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of eosinophlic esophagitis with swallowed topical corticosteroids.
    Nennstiel S; Schlag C
    World J Gastroenterol; 2020 Sep; 26(36):5395-5407. PubMed ID: 33024392
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Swallowed topical corticosteroids for eosinophilic esophagitis: Utilization and real-world efficacy from the EoE CONNECT registry.
    Laserna-Mendieta EJ; Navarro P; Casabona-Francés S; Savarino EV; Amorena E; Pérez-Martínez I; Guagnozzi D; Blas-Jhon L; Betoré E; Guardiola-Arévalo A; Pellegatta G; Krarup AL; Perello A; Barrio J; Gutiérrez-Junquera C; Teruel Sánchez-Vegazo C; Fernández-Fernández S; Naves JE; Oliva S; Rodríguez-Oballe JA; Carrión S; Espina S; Llorente Barrio M; Masiques-Mas ML; Dainese R; Feo-Ortega S; Martín-Dominguez V; Fernández-Pacheco J; Pérez-Fernández MT; Ghisa M; Maniero D; Nantes-Castillejo Ó; Nicolay-Maneru J; Suárez A; Maray I; Llerena-Castro R; Ortega-Larrodé A; Alcedo J; Granja Navacerrada A; Racca F; Santander C; Arias Á; Lucendo AJ;
    United European Gastroenterol J; 2024 Jun; 12(5):585-595. PubMed ID: 38284792
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel corticosteroid formulations in the treatment of eosinophilic esophagitis: what is the evidence?
    Walgraeve S; Vanuytsel T
    Acta Gastroenterol Belg; 2023; 86(3):437-448. PubMed ID: 37814560
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug treatment strategies for eosinophilic esophagitis in adults.
    Lucendo AJ
    Expert Opin Pharmacother; 2022 May; 23(7):827-840. PubMed ID: 35379069
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Eosinophilic esophagitis--treatment of eosinophilic esophagitis with drugs: corticosteroids.
    von Arnim U; Malfertheiner P
    Dig Dis; 2014; 32(1-2):126-9. PubMed ID: 24603395
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of eosinophilic esophagitis in the pediatric patient: an evidence-based approach.
    Munoz-Persy M; Lucendo AJ
    Eur J Pediatr; 2018 May; 177(5):649-663. PubMed ID: 29549437
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Update on Emerging Pharmacologic Therapies for Patients With Eosinophilic Esophagitis.
    Syverson EP; Hait E
    Gastroenterol Hepatol (N Y); 2022 Apr; 18(4):207-212. PubMed ID: 35505944
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emerging therapies for eosinophilic esophagitis.
    Greuter T; Hirano I; Dellon ES
    J Allergy Clin Immunol; 2020 Jan; 145(1):38-45. PubMed ID: 31705907
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of Budesonide Orodispersible Tablets as Induction Therapy for Eosinophilic Esophagitis in a Randomized Placebo-Controlled Trial.
    Lucendo AJ; Miehlke S; Schlag C; Vieth M; von Arnim U; Molina-Infante J; Hartmann D; Bredenoord AJ; Ciriza de Los Rios C; Schubert S; Brückner S; Madisch A; Hayat J; Tack J; Attwood S; Mueller R; Greinwald R; Schoepfer A; Straumann A;
    Gastroenterology; 2019 Jul; 157(1):74-86.e15. PubMed ID: 30922997
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Delayed hypersensitivity reaction to orodispersible budesonide in a case with eosinophilic esophagitis.
    Andrist CM; Jörg L; Greuter T; Gschwend A; Straumann A; Helbling A
    BMC Gastroenterol; 2020 Dec; 20(1):419. PubMed ID: 33308158
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Topical steroids in eosinophilic esophagitis: Systematic review and meta-analysis of placebo-controlled randomized clinical trials.
    Murali AR; Gupta A; Attar BM; Ravi V; Koduru P
    J Gastroenterol Hepatol; 2016 Jun; 31(6):1111-9. PubMed ID: 26699695
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Treatment of eosinophilic esophagitis - advancements and perspectives].
    Miehlke S; von Arnim U; Schlag C; Labenz J; Madisch A
    Z Gastroenterol; 2021 Aug; 59(8):869-878. PubMed ID: 34157757
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent insights on the use of topical steroids in eosinophilic esophagitis.
    Reddy A; Ashat D; Murali AR
    Expert Rev Gastroenterol Hepatol; 2020 Oct; 14(10):953-963. PubMed ID: 32567417
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Budesonide Orodispersible Tablets Maintain Remission in a Randomized, Placebo-Controlled Trial of Patients With Eosinophilic Esophagitis.
    Straumann A; Lucendo AJ; Miehlke S; Vieth M; Schlag C; Biedermann L; Vaquero CS; Ciriza de Los Rios C; Schmoecker C; Madisch A; Hruz P; Hayat J; von Arnim U; Bredenoord AJ; Schubert S; Mueller R; Greinwald R; Schoepfer A; Attwood S;
    Gastroenterology; 2020 Nov; 159(5):1672-1685.e5. PubMed ID: 32721437
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Treatment of eosinophilic esophagitis - advancements and perspectives].
    Miehlke S; Arnim UV; Schlag C; Labenz J; Madisch A
    Laryngorhinootologie; 2023 May; 102(5):339-348. PubMed ID: 37141876
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histologic and Clinical Effects of Different Topical Corticosteroids for Eosinophilic Esophagitis: Lessons from an Updated Meta-Analysis of Placebo-Controlled Randomized Trials.
    de Heer J; Miehlke S; Rösch T; Morgner A; Werner Y; Ehlken H; Becher H; Aigner A
    Digestion; 2021; 102(3):377-385. PubMed ID: 32610332
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Eosinophilic Esophagitis: Impact of Latest Insights Into Pathophysiology on Therapeutic Strategies.
    Schoepfer A; Safroneeva E; Straumann A
    Dig Dis; 2016; 34(5):462-8. PubMed ID: 27333298
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Swallowed topical corticosteroids reduce the risk for long-lasting bolus impactions in eosinophilic esophagitis.
    Kuchen T; Straumann A; Safroneeva E; Romero Y; Bussmann C; Vavricka S; Netzer P; Reinhard A; Portmann S; Schoepfer AM
    Allergy; 2014 Sep; 69(9):1248-54. PubMed ID: 24894658
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.